EGFR and lung adenocarcinoma: Having established this novel RCRA ChIP-seq procedure, we performed H3K27ac ChIP-seq for 69 lung adenocarcinomas (LUADs) using a dual-arm robot, revealing that driver mutations in EGFR were epigenetically distinguishable from pan-negative cases.